What question did this study set out to answer?

The aim is to assess the effectiveness of fluvoxamine and metformin in reducing fatigue associated with long COVID.

April 1, 2026

The Effect of Fluvoxamine and Metformin for Fatigue in Patients With Long COVID

The aim is to assess the effectiveness of fluvoxamine and metformin in reducing fatigue associated with long COVID.
Assessing patient symptoms pre- and post-treatment with fluvoxamine and metformin
Utilizing standardized fatigue measurement scales
Comparing results among participants with long COVID
Reduction in fatigue levels among patients using fluvoxamine
Improvement in overall wellbeing noted with metformin usage
Combination of both medications shows potential for enhanced effects

Postacute sequelae of SARS-CoV-2, or long COVID, presents a major therapeutic challenge, with fatigue being a prevalent and debilitating symptom.